|3.||B-Cell Lymphoma (Lymphoma, B Cell)
|4.||Neoplasm Metastasis (Metastasis)
|1.||Singh, Sukh Mahendra: 22 articles (12/2014 - 02/2003)|
|2.||Ohshima, Koichi: 16 articles (12/2015 - 06/2002)|
|3.||O'Connor, Owen A: 15 articles (09/2015 - 11/2006)|
|4.||Jaffe, Elaine S: 14 articles (11/2015 - 05/2003)|
|5.||Gaulard, Philippe: 13 articles (10/2015 - 07/2003)|
|6.||Bates, Susan E: 13 articles (07/2015 - 06/2004)|
|7.||Kim, Won Seog: 12 articles (11/2015 - 07/2007)|
|8.||Nakamura, Shigeo: 12 articles (04/2015 - 06/2003)|
|9.||Piekarz, Richard L: 11 articles (07/2015 - 06/2004)|
|10.||Zhang, Qian: 11 articles (12/2013 - 05/2005)|
12/01/1986 - "An immunocytochemical study of T-cell lymphomas using monoclonal and polyclonal antibodies effective in routinely fixed wax embedded tissues."
01/01/2010 - "By contrast, programed death-1 immunohistochemical staining and double labeling using antibodies specific for BCL-6 and CD3 were helpful in appreciating the follicular T-helper cell immunophenotype of angioimmunoblastic T-cell lymphoma."
10/01/2009 - "The objective of this study was to evaluate a panel of antibodies that would allow greater diagnostic accuracy of ALL and evaluate the frequency of FLI-1 immunoreactivity in a series of ALL cases and an expanded series of T-cell lymphoma subtypes. "
01/01/2014 - "In a mouse model of human T-cell lymphoma, significant survival benefit was demonstrated for animals treated with the newly selected anti-CCR4 antibodies. "
01/01/2010 - "Secondly, the patient developed an early form of a second independent T-cell lymphoma (refractory sprue type II) under a strict GFD, then with CD-associated antibodies, which raises the question whether the clonal intraepithelial lymphocytes were stimulating antibody production. "
|2.||Doxorubicin (Adriamycin)FDA LinkGeneric
11/01/2010 - "Alternative protocols should be considered for dogs with T-cell lymphoma that do not respond to doxorubicin."
11/01/2010 - "Many dogs with T-cell lymphoma did not respond to doxorubicin; therefore, multiagent protocols containing doxorubicin may not be optimal. "
11/01/2010 - "Response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell lymphoma: 41 cases (2006-2008)."
06/01/2005 - "The dose of adriamycin had no influence on local control of T-cell lymphoma. "
06/01/2005 - "There were no recurrences in DLBCL patients who received chemotherapy in which the doses of adriamycin were > 200 mg/m(2), nor in DLBCL patients who were treated with > 45 Gy. Only nine of 15 patients with T-cell lymphoma treated with < or = 50 Gy and three of five patients treated with > 50 Gy had local control. "
|3.||romidepsin (FK228)FDA Link
08/01/2011 - "As a T-cell lymphoma drug, romidepsin offers a valuable new treatment for diseases with few effective therapies."
08/01/2013 - "These initial results observed with single-agent romidepsin provide a foundation for exploring combination strategies and demonstrates proof-of-principle that other such drugs with similar mechanisms of action may be effective in T-cell lymphoma. "
05/01/2004 - "FR901228, FK228, or depsipeptide, is an HDAC inhibitor effective in T-cell lymphomas. "
05/16/2013 - "Gene expression analysis of samples obtained from patients with CTCL enrolled on the NCI1312 phase 2 study of romidepsin in T-cell lymphoma suggested perturbation of the MAPK pathway by romidepsin. "
12/01/2010 - "The efficacy and safety profile of romidepsin in clinical trials in T-cell lymphoma is reviewed, and emerging data on single-agent and combination strategies in myeloid and B-lymphoid malignancies is outlined. "
|4.||alemtuzumab (Campath)FDA Link
11/01/2013 - "Intense reinduction therapy followed by reduced-intensity BEAM-alemtuzumab conditioning and allogeneic HSCT is effective and offers curative potential for patients with advanced T cell lymphomas, even for those not in remission. "
01/01/2007 - "Campath-1H or alemtuzumab, a human anti-CD52, has been shown to be effective in T-cell malignancies; however, there is very limited information on CD52 expression in T-cell lymphoma (TCL). "
03/01/2006 - "Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab."
05/01/2012 - "Published literature and abstract proceedings were scanned, and a systematic review of phase II studies administering alemtuzumab in patients with T-cell lymphomas was performed. "
05/01/2005 - "Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma."
|5.||Cyclosporine (Ciclosporin)FDA LinkGeneric
05/01/2010 - "[Therapeutic efficacy of cyclosporin A for refractory angioimmunoblastic T cell lymphoma]."
10/01/1999 - "Recently, we gave oral cyclosporin A (CsA) to a patient with IBL-like T-cell lymphoma, and succeeded in achieving dramatic remission. "
03/01/2007 - "Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine."
03/01/2000 - "We applied oral cyclosporin A (CsA) treatment to two cases of IBL-like T-cell lymphoma, and succeeded in achieving complete remissions. "
03/01/2000 - "Successful treatment of IBL-like T-cell lymphoma with cyclosporin A: two case reports with special reference to serum cytokine levels."
02/01/1990 - "Only one of the T-cell lymphomas was identified in paraffin studies. "
12/01/2004 - "Application of combined immunofluorescence and fluorescence in situ hybridization on paraffin-embedded sections to characterize T-cell lymphoma with EBV-infected B-cell blasts."
01/01/2004 - "Cytometric immunophenotyping of bone marrow and immunohistochemical paraffin section staining of bone marrow biopsies in 53 B- and T-cell lymphoma patients were performed. "
01/01/2004 - "PCR diagnosis of T-cell lymphoma in paraffin-embedded bone marrow biopsies."
03/01/2003 - "Twenty cases of paraffin-embedded nasopharyngeal NK/T cell lymphomas tissues were studied by using methylation specific PCR (MSP). "
08/01/2013 - "We review several classes of novel treatment for T-cell lymphomas including monoclonal antibodies, epigenetic modifiers, newer generation of cytotoxics, and specific targeting agents that may improve treatment outcome. "
01/01/1983 - "Candidate counterparts of Sézary cells and adult T-cell lymphoma-leukaemia cells in normal peripheral blood: an ultrastructural study with the immunogold method and monoclonal antibodies."
01/01/2011 - "The monoclonal antibodies against ASNS have been successfully prepared, which provides a tool for the following research of nasal type NK/T cell lymphoma."
01/01/2007 - "The paraffine sections were stained by routine histochemical and an immunohistochemical method by using monoclonal antibodies for both B-cell and T-cell lymphomas, due to the verification of lymphoepithelial lesions. "
10/15/1989 - "For their establishment as T-cell lymphoma a panel of monoclonal antibodies is needed."
|8.||Vincristine (Oncovin)FDA LinkGeneric
08/01/2010 - "Based on the initial diagnosis of an invasive periphere malignant T-cell lymphoma of the liver a pre-phase treatment with vincristine, prednisolone followed by one cycle of CHOEP were administered. "
01/01/2015 - "These findings suggested that combined active immunotherapy can be developed as a promising treatment for T cell lymphoma, which may further improve the effectiveness of the current standard cyclophosphamide, DOX, vincristine and prednisone (CHOP) therapy."
01/01/2015 - "NK/T cell lymphoma concurrent with aplastic anemia was diagnosed and a mild chemotherapy regimen including vincristine, prednisone, L-asparaginase was administered. "
03/01/1982 - "Twelve of 13 adult patients with acute lymphocytic leukemia, acute undifferentiated leukemia, or convoluted T-cell lymphoma (T-cell ALL) who were treated with Adriamycin, vincristine, and prednisone achieved a complete remission. "
03/01/2001 - "The present study aimed to analyse the treatment outcome of four cycles of CHOP (cyclophosphamide-vincristine-doxorubicin-prednisolone) followed by involved field radiation therapy (IF RT) for the treatment of stage I-II nasal natural killer (NK)/T-cell lymphoma. "
03/01/2013 - "This paper discusses the pharmacokinetics and efficacy of pralatrexate in T-cell lymphoma in clinical trials. "
04/01/2009 - "Because of the limited therapies available for aggressive T-cell lymphoma, pralatrexate could secure a niche for the treatment of this condition, provided on going clinical trials and future phase III trials confirm the efficacy of the drug."
09/01/2011 - "Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma."
03/01/2013 - "Currently, the potential synergy between pralatrexate and other agents in T-cell lymphoma is being explored in a number of studies. "
09/01/2011 - "Pralatrexate has significant activity in vitro, and in early Phase I/II trials, responses were noted in patients with aggressive T-cell lymphomas. "
12/01/2008 - "Further studies revealed that the cells were CD56+, T-cell-restricted intracellular antigen-1+, and contained Epstein-Barr virus sequences consistent with a nasal-type NK/T-cell lymphoma. "
01/01/1997 - "This is the first study of its kind regarding the effect of the ascitic growth of any T cell lymphoma on various aspects of the immune response to exogenous antigens and the correlation thereof with an immunomodulator."
09/01/2015 - "In humans, flow cytometry (FC) allows a definitive diagnosis of T-cell lymphoma based on high prevalence of antigen aberrancies. "
01/01/2011 - "We identified nine PTCL, NOS-associated antigens whose immunological reactivity was further investigated using sera from 52 B- and T-cell lymphoma patients and 17 normal controls. "
11/01/2009 - "Herein is presented a case of FDCS of the small intestine with positivity for T-cell antigen, simulating T-cell lymphoma. "
|1.||Drug Therapy (Chemotherapy)
07/01/2001 - "These findings confirm that chemotherapy gives a low complete remission rate in localized nasal NK/T cell lymphoma. "
03/01/2014 - "Several prospective clinical trials are evaluating the role of high dose chemotherapy as a consolidation in first-line treatment for T-cell lymphoma including AITL."
05/01/2006 - "High intensified radiation therapy followed by chemotherapy may be effective for localized nasal NK/T-cell lymphoma."
01/01/2000 - "These observations suggest that double high-dose chemotherapy with PBSCT support may be effective in resistant nasal NK/T-cell lymphoma."
05/01/2010 - "The prognosis of angioimmunoblastic T cell lymphoma (AITL) is poor because of chemotherapy-resistance and the short duration of remission. "
05/01/2012 - "Because only a limited amount of data is available on laryngeal NK/T-cell lymphoma, the mainstay of treatment remains unclear, although some data suggest that radiotherapy alone is the best option. "
03/01/2014 - "Diagnosed as nasal type of NK/T cell lymphoma via a tissue biopsy, it was managed by chemo-radiotherapy leading to complete resolution of symptoms and disease free on his follow-up 6 months later."
03/01/2013 - "The purposes of this study are to evaluate prognosis in patients with locoregionally recurrent extranodal nasal-type NK/T cell lymphoma (NKTCL) and to determine the value of salvage radiotherapy. "
04/01/2012 - "This study aims to evaluate the outcome and pattern of failure in a large cohort of patients with Stage I NK/T-cell lymphoma of the upper aerodigestive tract treated with radiotherapy alone. "
11/15/2011 - "This study aimed to evaluate the failure patterns and clinical implications in patients with early stage nasal natural killer (NK)/T-cell lymphoma treated with primary radiotherapy. "
|3.||Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation)
03/01/2014 - "A 50-year-old male with T-cell lymphoma presented for autologous peripheral blood stem cell transplantation. "
08/01/2006 - "Here we report a case of T-cell PTLD which occurred after autologous peripheral blood stem cell transplantation (PBSCT) for relapsed angioimmunoblastic T-cell lymphoma (AILT). "
08/01/2003 - "We report a 19-year-old man with extranodal natural killer (NK)/T cell lymphoma, nasal type treated by allogeneic peripheral blood stem cell transplantation (allo-PBSCT). "
05/01/2003 - "We describe a patient with natural killer (NK)/T cell lymphoma who relapsed after autologous peripheral blood stem cell transplantation (auto-PBSCT) and was successfully treated with Escherichia coli (E. "
12/01/2001 - "Because her NK/T-cell lymphoma was highly aggressive and chemo-resistant, she underwent autologous peripheral blood stem cell transplantation (PBSCT). "
|4.||Stem Cell Transplantation
09/01/2015 - "Role of autologous stem cell transplantation in T-cell lymphoma patients: a single institution retrospective analysis."
09/01/2015 - "Successful stem cell transplantation in a patient with primary cutaneous aggressive cytotoxic epidermotropic CD8+ T-cell lymphoma."
05/01/2015 - "We studied the roles of autologous (A) and allogeneic (allo) stem cell transplantation (SCT) in the treatment of 134 patients with T cell lymphoma (TCL) at our center. "
05/01/2015 - "Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease."
01/01/2015 - "Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma."
|5.||Transplantation (Transplant Recipients)
11/01/2007 - "Sustained complete remission of refractory enteropathy-type T-cell lymphoma following reduced-intensity unrelated cord blood transplantation."
05/01/2014 - "A 46-year-old woman developed EBA 4 years after allogenic cord blood transplantation for non-Hodgkin T-cell lymphoma complicated by acute digestive and cutaneous GVHD. "
01/01/2012 - "T-cell lymphoma/Sézary syndrome in a liver transplant recipient."
01/01/2012 - "Transplantation of HSCs expressing MYC into syngeneic recipient mice resulted in development of AML and T-cell lymphomas within 7-9 weeks as expected. "
05/01/2011 - "More than 40 experts from around the world presented updates on classification, epidemiology and prognosis; rare and T-cell lymphomas of unspecified origin, CD30(+) T-cell lymphomas; new treatment strategies; new agents and rational combinations; and transplantation. "